Full Breakdown
Medicare Secures 71% Discount on Novo Nordisk's Ozempic and Wegovy
11/26/2025, 10:02:45 AM
Overview of the Negotiation Outcome
On November 25, 2025, the U.S. government announced a significant 71% discount on the list prices of Novo Nordisk A/S's popular medications, Ozempic and Wegovy, for Medicare patients. This negotiation is part of the broader implementation of the Inflation Reduction Act, a law enacted during President Joe Biden's administration aimed at reducing drug costs for the elderly. The new pricing will take effect in 2027 and is expected to impact approximately 3 million Medicare beneficiaries who utilized these medications in 2024.
Implications for Drug Pricing
The Centers for Medicare and Medicaid Services (CMS) indicated that this negotiation represents a shift in how drug prices are set, moving from individual insurance plans negotiating prices to Medicare negotiating on behalf of all beneficiaries. This change guarantees minimum discounts based on the duration a drug has been on the market. Other notable medications affected include Pfizer Inc.'s Ibrance, which will see a 50% price reduction, and GSK Plc's Trelegy Ellipta, with a 73% discount.
Industry Reactions and Concerns
Novo Nordisk expressed serious concerns regarding the implications of the Inflation Reduction Act on patients, maintaining its opposition to government price setting. A spokesperson stated that the company is apprehensive about how the law is being implemented. Additionally, Novo has filed a lawsuit against the federal government, claiming that the Medicare drug price negotiation program is unconstitutional. The company argues that Ozempic and Wegovy should be treated as separate drugs due to their distinct uses, despite sharing the same active ingredient.
Criticism from Pharmaceutical Groups
The Pharmaceutical Research and Manufacturers of America criticized the government's approach, with spokesperson Alex Schriver stating, “Government price setting for medicines is the wrong policy.” This sentiment reflects broader industry concerns regarding the potential long-term effects of government negotiations on drug innovation and availability.
Broader Context of Drug Pricing
The negotiations are part of a series of actions taken by the Biden administration to address rising healthcare costs and the disparity in drug pricing between the U.S. and other countries. The Trump administration had previously utilized tariffs and regulatory measures to pressure drug manufacturers into lowering prices. The ongoing negotiations and price cuts are seen as a response to public outcry over high medication costs, particularly for essential drugs like Ozempic and Wegovy, which have gained prominence in treating obesity and diabetes.
What's Next for Drug Pricing?
As the Medicare price negotiations continue, the pharmaceutical industry is bracing for further scrutiny and potential changes in pricing strategies. The next round of negotiations is anticipated to include additional medications, with the implications of these changes likely to resonate throughout the healthcare sector. The outcome of Novo's lawsuit and the ongoing discussions surrounding drug pricing will be pivotal in shaping the future landscape of pharmaceutical costs in the United States.
